SNCA and synucleinopathy: Since we reported the unexpected discovery of α-synuclein in the CSF and peripheral blood plasma [13], several groups have examined the potential use of α-synuclein as a putative biomarker for PD and other α-synucleinopathies, but the results have been inconclusive [16]–[19], [30]–[33].